Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Barbara L. Weber M.D. | President, CEO & Director | 1.04M | -- | 1957 |
Dr. Adam S. Crystal M.D., Ph.D. | President of Research & Development | 977.22k | -- | 1977 |
Dr. Alan Ashworth FRS, Ph.D. | Founder & Member of Scientific Advisory Board | -- | -- | 1961 |
Dr. Levi Garraway M.D., Ph.D. | Founder | -- | -- | 1969 |
Dr. William G. Kaelin Jr., M.D. | Founder & Member of Scientific Advisory Board | -- | -- | 1958 |
Dr. Timothy K. Lu M.D., Ph.D. | Founder | -- | -- | 1981 |
Dr. Antoni Ribas M.D., Ph.D. | Founder & Member of Scientific Advisory Board | -- | -- | 1967 |
Mr. Timothy Redfern | Chief Financial Officer | -- | -- | 1979 |
Mr. Jannik N. Andersen Ph.D. | Chief Scientific Officer | -- | -- | -- |
Mr. Douglas J. Barry Esq., J.D. | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | -- | -- | 1970 |
Tango Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 140
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Corporate Governance
Upcoming Events
August 5, 2024 at 12:30 PM UTC - August 9, 2024 at 12:30 PM UTC
Tango Therapeutics, Inc. Earnings Date